Hematologic Malignancies Testing Global Market Report 2025
상품코드:1760548
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
혈액 악성 종양 검사 시장 규모는 향후 몇 년 동안 연평균 13.4%의 성장세를 보이며 2029년에는 59억 4,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 맞춤형 암 치료에 대한 수요 증가, 차세대 시퀀서 보급, 신흥 시장에서의 헬스케어 지출 증가, 정밀 종양학 이니셔티브의 확대, 혈액암 치료에 초점을 맞춘 임상시험의 증가 등입니다. 예상되는 주요 동향으로는 분자 검사 기술의 발전, 자동화 및 고처리량 진단 플랫폼의 개발, 혈액 악성 종양에 대한 지속적인 연구와 혁신, 검사 해석에 인공지능의 통합, 혈액암에 대한 액체 생검법의 획기적인 발전 등을 꼽았습니다.
암 진단 건수의 증가는 향후 몇 년 동안 혈액 악성 종양 검사 시장의 성장을 견인할 것으로 예상됩니다. 암 진단은 영상 검사, 임상 검사, 생검 등 다양한 의학적 검사 및 평가를 통해 환자의 암 유무, 종류, 병기를 확인합니다. 암 진단의 증가는 검진 프로그램에 대한 접근성이 개선되고 일반 대중의 인식이 높아져 조기 발견이 가능해졌기 때문입니다. 혈액 악성 종양 검사는 혈액 관련 암의 조기 발견, 정확한 분류 및 모니터링을 가능하게함으로써 암 진단을 지원하고, 궁극적으로 표적 치료 결정을 유도하여 환자의 예후를 개선할 수 있습니다. 예를 들어, 미국 비영리단체인 미국암협회에 따르면, 2024년 미국에서 새로 암 진단을 받은 환자 수는 200만 명을 넘어 전년 대비 4% 증가할 것으로 예상됩니다. 따라서 암 진단 건수의 증가는 혈액 악성 종양 검사 시장의 성장을 촉진하고 있습니다.
혈액 악성 종양 검사 시장의 주요 기업들은 의료진에게 혈액암의 조기 발견, 치료 계획 및 모니터링을 개선하는 정확하고 시기적절한 진단 도구를 제공하기 위해 신속 분자 프로파일링과 같은 혁신적인 진단 방법에 집중하고 있습니다. 신속 분자 프로파일링은 환자의 유전자 프로파일을 분석하여 돌연변이 및 변이를 식별하는 진단 기술로, 보다 신속하고 개별화된 치료 방침을 결정할 수 있게 해줍니다. 예를 들어, 2023년 11월 미국 암센터인 로즈웰파크 종합암센터는 백혈병, 림프종, 다발성 골수종 등 혈액암을 보다 정확하고 빠르게 진단할 수 있도록 설계된 차세대 유전자 염기서열 분석 도구인 판헴(PanHeme)을 발표하였습니다. 이 검사는 72시간 내에 수백 개의 유전자 돌연변이를 검출하여 진단의 속도와 정확성을 크게 향상시켜 보다 맞춤화된 치료 계획을 지원합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 혈액 악성 종양 검사 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 혈액 악성 종양 검사 시장 : 성장률 분석
세계의 혈액 악성 종양 검사 시장 실적 : 규모와 성장, 2019-2024년
세계의 혈액 악성 종양 검사 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 혈액 악성 종양 검사 전체 시장(TAM)
제6장 시장 세분화
세계의 혈액 악성 종양 검사 시장 : 테스트 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
전혈구수(CBC)
유세포 분석
분자 검사
유전자 검사
기타 테스트 종류
세계의 혈액 악성 종양 검사 시장 : 제품별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
키트
서비스
세계의 혈액 악성 종양 검사 시장 : 기술별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
중합효소 연쇄 반응(PCR)
차세대 시퀀싱(NGS)
면역조직화학(IHC)
세포유전학
기타 기술
세계의 혈액 악성 종양 검사 시장 : 치료 적응증별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
백혈병
림프종
다발성 골수종
골수 증식성 종양
기타 치료 적응증
세계의 혈액 악성 종양 검사 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
진단 실험실
학술조사기관
기타 최종사용자
세계의 혈액 악성 종양 검사 시장, 전혈구 산정(CBC) 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
헤모글로빈 검사
헤마토크릿 측정
백혈구수
적혈구수
혈소판수
평균 적혈구 용적(MCV)
평균 적혈구 헤모글로빈(MCH)
세계의 혈액 악성 종양 검사 시장, 유세포 분석 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
면역 표현형 검사
세포 주기 분석
아포토시스 검출
미세잔존질환(MRD) 검사
DNA 함유량 분석
세계의 혈액 악성 종양 검사 시장, 분자 검사 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
중합효소 연쇄 반응(PCR)
차세대 시퀀싱(NGS)
역전사 PCR(RT-PCR)
FISH(Fluorescent In Situ Hybridization)
마이크로어레이 해석
세계의 혈액 악성 종양 검사 시장, 유전자 검사 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
생식세포 변이 검사
체세포 변이 검사
세포유전학적 검사
염색체 이상 검출
단일염기다형(SNP) 해석
세계의 혈액 악성 종양 검사 시장, 기타 테스트 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
골수 생검
면역조직화학(IHC)
효소 어세이
혈청 단백질 전기영동(SPEP)
영상 검사
제7장 지역별·국가별 분석
세계의 혈액 악성 종양 검사 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 혈액 악성 종양 검사 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
혈액 악성 종양 검사 시장 : 경쟁 구도
혈액 악성 종양 검사 시장 : 기업 개요
Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Abbott Laboratories
Novartis Aktiengesellschaft
GlaxoSmithKline Public Limited Company
Eli Lilly and Company
Laboratory Corporation of America Holdings
Agilent Technologies Inc.
Sun Pharmaceutical Industries Limited
Illumina Inc.
Bio-Rad Laboratories Inc.
Cipla Limited
Hikma Pharmaceuticals PLC
Lupin Limited
Invitae Corporation
Adaptive Biotechnologies Corporation
Invivoscribe Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
혈액 악성 종양 검사 시장 2029년 : 새로운 기회를 제공하는 국가
혈액 악성 종양 검사 시장 2029년 : 새로운 기회를 제공하는 부문
혈액 악성 종양 검사 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Hematologic malignancies testing involves diagnostic and monitoring procedures aimed at detecting, classifying, and assessing cancers of the blood, bone marrow, and lymphatic system. This testing provides precise identification of the type and subtype of malignancy, helps determine prognosis, informs treatment strategies, and tracks treatment response or disease relapse.
The primary types of tests for hematologic malignancies include complete blood count (CBC), flow cytometry, molecular testing, genetic testing, and other methods. A complete blood count (CBC) measures various blood components such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. Products in this area are classified as kits and services. Technologies employed include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), cytogenetics, among others. These tests address therapeutic indications like leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and more. They are utilized by a range of end-users including hospitals, diagnostic laboratories, academic institutions, research centers, and others.
The hematologic malignancies testing market research report is one of a series of new reports from The Business Research Company that provides hematologic malignancies testing market statistics, including the hematologic malignancies testing industry global market size, regional shares, competitors with the hematologic malignancies testing market share, detailed hematologic malignancies testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hematologic malignancies testing industry. This hematologic malignancies testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hematologic malignancies testing market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth during the historic period can be attributed to an increasing incidence of blood cancers, heightened awareness of early cancer detection, expanded use of flow cytometry and molecular diagnostics, growth in hematology testing across hospitals and laboratories, and improved availability of reimbursement for cancer diagnostic procedures.
The hematologic malignancies testing market size is expected to see rapid growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The projected growth in the forecast period is driven by increasing demand for personalized cancer treatments, wider adoption of next-generation sequencing, rising healthcare expenditures in emerging markets, expansion of precision oncology initiatives, and a growing number of clinical trials focused on blood cancer therapies. Key trends expected include advancements in molecular testing technologies, the development of automated and high-throughput diagnostic platforms, ongoing research and innovation in hematologic malignancies, integration of artificial intelligence in test interpretation, and breakthroughs in liquid biopsy methods for blood cancers.
The increasing number of cancer diagnoses is expected to drive the growth of the hematologic malignancies testing market in the coming years. Cancer diagnosis involves identifying the presence, type, and stage of cancer in a patient through various medical tests and evaluations such as imaging, laboratory tests, and biopsies. The rise in cancer diagnoses is attributed to improved access to screening programs and greater public awareness, leading to earlier detection. Hematologic malignancies testing supports cancer diagnosis by enabling early detection, accurate classification, and monitoring of blood-related cancers, which ultimately helps guide targeted treatment decisions and improves patient outcomes. For example, according to the American Cancer Society, a US-based nonprofit organization, over 2 million new cancer cases were diagnosed in the US in 2024, marking a 4% increase from previous years. Therefore, the rising number of cancer diagnoses is driving growth in the hematologic malignancies testing market.
Leading companies in the hematologic malignancies testing market are focusing on innovative diagnostic methods, such as rapid molecular profiling, to provide healthcare professionals with precise and timely diagnostic tools that improve early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic technique that analyzes a patient's genetic profile to identify mutations and variations, allowing for faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based cancer center, launched PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers like leukemia, lymphoma, and multiple myeloma with greater accuracy and speed. This test detects mutations in hundreds of genes within 72 hours, significantly enhancing the speed and precision of diagnosis and supporting more personalized treatment plans.
In January 2025, Adaptive Biotechnologies Corporation, a US-based biotechnology firm specializing in hematologic malignancies testing, partnered with NeoGenomics Laboratories, Inc. to expand personalized disease monitoring for blood cancer patients. Through this collaboration, Adaptive Biotechnologies and NeoGenomics aim to broaden access to precise minimal residual disease monitoring in blood cancers by incorporating the clonoSEQ test into NeoGenomics' diagnostic services, thereby improving treatment decisions and disease tracking. NeoGenomics Laboratories Inc. is a US-based public, high-complexity clinical laboratory specializing in cancer genetics diagnostic testing.
Major players in the hematologic malignancies testing market are Johnson & Johnson Private Limited, F. Hoffmann-La Roche Aktiengesellschaft, Merck & Co. Inc., Bayer Aktiengesellschaft, AstraZeneca PLC, Abbott Laboratories, Novartis Aktiengesellschaft, GlaxoSmithKline Public Limited Company, Eli Lilly and Company, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Sun Pharmaceutical Industries Limited, Illumina Inc., Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Invitae Corporation, Adaptive Biotechnologies Corporation, Invivoscribe Inc.
North America was the largest region in the hematologic malignancies testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hematologic malignancies testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hematologic malignancies testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hematologic malignancies testing market consists of revenues earned by entities by providing biopsy testing, cytogenetic testing, and molecular testing (PCR, NGS). The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancies testing market also includes sales of hematology analyzers, and bone marrow biopsy kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hematologic Malignancies Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hematologic malignancies testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hematologic malignancies testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hematologic malignancies testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Test Type: Complete Blood Count (CBC); Flow Cytometry; Molecular Testing; Genetic Testing; Others Test Type
3. Hematologic Malignancies Testing Market Trends And Strategies
4. Hematologic Malignancies Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Hematologic Malignancies Testing Growth Analysis And Strategic Analysis Framework
5.1. Global Hematologic Malignancies Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hematologic Malignancies Testing Market Growth Rate Analysis
5.4. Global Hematologic Malignancies Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hematologic Malignancies Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hematologic Malignancies Testing Total Addressable Market (TAM)
6.1. Global Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Complete Blood Count (CBC)
Flow Cytometry
Molecular Testing
Genetic Testing
Others Test Type
6.2. Global Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Kits
Services
6.3. Global Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohisto Chemistry (IHC)
Cytogenetics
Others Technology
6.4. Global Hematologic Malignancies Testing Market, Segmentation By Therapeutic Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Leukemia
Lymphoma
Multiple Myeloma
Myeloproliferative Neoplasms
Others Therapeutic Indication
6.5. Global Hematologic Malignancies Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Diagnostic Labs
Academic And Research Institutions
Others End Users
6.6. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Complete Blood Count (CBC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hemoglobin Testing
Hematocrit Measurement
White Blood Cell Count
Red Blood Cell Count
Platelet Count
Mean Corpuscular Volume (MCV)
Mean Corpuscular Hemoglobin (MCH)
6.7. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Flow Cytometry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunophenotyping
Cell Cycle Analysis
Apoptosis Detection
Minimal Residual Disease (MRD) Testing
DNA Content Analysis
6.8. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Molecular Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Reverse Transcriptase-PCR (RT-PCR)
Fluorescence In Situ Hybridization (FISH)
Microarray Analysis
6.9. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Genetic Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Germline Mutation Testing
Somatic Mutation Testing
Cytogenetic Testing
Chromosomal Aberration Detection
Single Nucleotide Polymorphism (SNP) Analysis
6.10. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Others Test Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bone Marrow Biopsy
Immunohistochemistry (IHC)
Enzyme Assays
Serum Protein Electrophoresis (SPEP)
Imaging Tests
7. Hematologic Malignancies Testing Market Regional And Country Analysis
7.1. Global Hematologic Malignancies Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hematologic Malignancies Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hematologic Malignancies Testing Market
9.1. China Hematologic Malignancies Testing Market Overview
9.2. China Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hematologic Malignancies Testing Market
10.1. India Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hematologic Malignancies Testing Market
11.1. Japan Hematologic Malignancies Testing Market Overview
11.2. Japan Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hematologic Malignancies Testing Market
12.1. Australia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hematologic Malignancies Testing Market
13.1. Indonesia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hematologic Malignancies Testing Market
14.1. South Korea Hematologic Malignancies Testing Market Overview
14.2. South Korea Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hematologic Malignancies Testing Market
15.1. Western Europe Hematologic Malignancies Testing Market Overview
15.2. Western Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hematologic Malignancies Testing Market
16.1. UK Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hematologic Malignancies Testing Market
18.1. France Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Hematologic Malignancies Testing Market
19.1. Italy Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Hematologic Malignancies Testing Market
20.1. Spain Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hematologic Malignancies Testing Market
21.1. Eastern Europe Hematologic Malignancies Testing Market Overview
21.2. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hematologic Malignancies Testing Market
22.1. Russia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hematologic Malignancies Testing Market
23.1. North America Hematologic Malignancies Testing Market Overview
23.2. North America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hematologic Malignancies Testing Market
24.1. USA Hematologic Malignancies Testing Market Overview
24.2. USA Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hematologic Malignancies Testing Market
26.1. South America Hematologic Malignancies Testing Market Overview
26.2. South America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hematologic Malignancies Testing Market
27.1. Brazil Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hematologic Malignancies Testing Market
28.1. Middle East Hematologic Malignancies Testing Market Overview
28.2. Middle East Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hematologic Malignancies Testing Market
29.1. Africa Hematologic Malignancies Testing Market Overview
29.2. Africa Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hematologic Malignancies Testing Market Competitive Landscape And Company Profiles
